» Articles » PMID: 33042331

MicroRNA-133b Represses the Progression of Lung Cancer Through Inhibiting SOX9/β-catenin Signaling Pathway

Overview
Specialty Pathology
Date 2020 Oct 12
PMID 33042331
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNA-133b (miR-133b) has been shown to be down-regulated in lung cancer and functions as a tumor repressor. However, the underlying mechanisms of miR-133b in lung cancer are not clear. SOX9, a member of SOX family, serves as an oncogene in lung cancer by activating b-catenin signaling and was identified to be a direct target of miR-133b in breast cancer. Based on these data, the current study was performed to explore whether SOX9/b-catenin signaling is implicated in miR-133b-meditaed lung cancer repression. MiR-133b expression in lung cancer tissues and cells were detected by RT-PCR. CCK-8, colony formation, flow cytometry, transwell chamber and assays were carried out to determine cell proliferation, colony formation, apoptosis, cell cycle, invasion, and tumorigenesis. We found that miR-133b expression was decreased in lung cancer tissues and cells. Up-regulation of miR-133b reduced cell proliferation and colony formation, induced cell apoptosis and G0/G1 phase arrest, and decreased cell invasion. Besides, miR-133b up-regulation decreased the expression of b-catenin and SOX9. Cell viability inhibition and apoptosis promotion induced by miR-133b up-regulation were all impaired when SOX9 was up-regulated. Furthermore, miR-133b over-expression repressed the tumorigenesis of lung cancer cells with smaller tumor size and lower Ki-67 expression. Taken together, this study clarifies that miR-133b represses lung cancer progression by inhibiting SOX9/b-catenin signaling.

Citing Articles

miRNA on the Battlefield of Cancer: Significance in Cancer Stem Cells, WNT Pathway, and Treatment.

Bhagtaney L, Dharmarajan A, Warrier S Cancers (Basel). 2024; 16(5).

PMID: 38473318 PMC: 10931375. DOI: 10.3390/cancers16050957.


Analysis of expression, immunomodulation and prognostic value in renal cancer using multiomic databases.

Ogbodo A, Mustafov D, Arora M, Lambrou G, Braoudaki M, Siddiqui S Heliyon. 2024; 10(2):e24286.

PMID: 38268823 PMC: 10803920. DOI: 10.1016/j.heliyon.2024.e24286.


Downregulation of Serum miR-133b and miR-206 Associate with Clinical Outcomes of Progression as Monitoring Biomarkers for Metastasis Colorectal Cancer Patients.

Wanram S, Klaewkla N, Pinyosri P Microrna. 2024; 13(1):56-62.

PMID: 38231064 PMC: 11275315. DOI: 10.2174/0122115366266024240101075745.


Deubiquitylase OTUD1 confers Erlotinib sensitivity in non-small cell lung cancer through inhibition of nuclear translocation of YAP1.

Liu H, Zhong L, Lu Y, Liu X, Wei J, Ding Y Cell Death Discov. 2022; 8(1):403.

PMID: 36182943 PMC: 9526728. DOI: 10.1038/s41420-022-01119-w.


The miR-133b/brefeldin A-inhibited guanine nucleotide-exchange protein 1 (ARFGEF1) axis represses proliferation, invasion, and migration in cervical cancer cells.

Jiang L, Wang X Bioengineered. 2022; 13(2):3323-3332.

PMID: 35048795 PMC: 8973932. DOI: 10.1080/21655979.2022.2027063.


References
1.
Jamieson C, Sharma M, Henderson B . Targeting the β-catenin nuclear transport pathway in cancer. Semin Cancer Biol. 2014; 27:20-9. DOI: 10.1016/j.semcancer.2014.04.012. View

2.
Yang L, Hou J, Cui X, Suo L, Lv Y . MiR-133b regulates the expression of CTGF in epithelial-mesenchymal transition of ovarian cancer. Eur Rev Med Pharmacol Sci. 2017; 21(24):5602-5609. DOI: 10.26355/eurrev_201712_14001. View

3.
Li X, Wan X, Chen H, Yang S, Liu Y, Mo W . Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer. Clin Cancer Res. 2014; 20(9):2312-25. DOI: 10.1158/1078-0432.CCR-13-1588. View

4.
Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

5.
Chen X, Wang K, Xu Z, Li S, Liu Q, Fu D . MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer Cell Int. 2014; 14:70. PMC: 4238049. DOI: 10.1186/s12935-014-0070-3. View